A series of 200 consecutive thin sections were generated from a high-grade serous ovarian tumor and laser microdissected four spatially separated "core" regions of tumor epithelium, along with tumor epithelium, stroma or whole tissue harvests at 200 µm intervals. These distinct tissue collections were analyzed by quantitative proteomics and RNA-Seq. Unsupervised analyses revealed co-clustering of tumor cores with enriched tumor epithelium, which were distinct from the enriched stroma and whole tumor collections. Strong correlations in protein and transcript abundance in tumor epithelium and stromal collections from neighboring thin sections were decreased in samples harvested just hundreds of microns apart. Stroma (mesenchymal) and tumor epithelium (differentiated) displayed a distinct association with ovarian cancer prognostic molecular sub-types with a 2-year difference in median survival. These data reveal substantial tumor microenvironment protein and transcript expression heterogeneity that directly bear on prognostic signatures and underscore the need to enrich cellular subpopulations for expression profiling.
Introduction
Ovarian cancer is the fifth leading cause of death in women in the U.S. [1] , with more than 22 ,000 new cases and nearly 14,000 deaths projected to occur in 2019. Most ovarian cancer cases are diagnosed at an advanced stage after accumulation of numerous genomic and molecular signaling alterations resulting in heterogeneous populations and subpopulations of tumor cells that confound successful therapeutic intervention. The 5-year survival rate of patients diagnosed with metastatic ovarian cancer is less than 30%.
Numerous high-throughput sequencing studies aimed at broadly characterizing the genomic landscape of specific cancer types have been or are being conducted. Although profoundly key in adding to our molecular understanding of cancer, these studies have resulted in limited clinical translation, due in part to an ever increasing body of evidence that points to previously underappreciated levels of heterogeneity in the tumor microenvironment (TME) [2] . Substantial molecular and pathologic differences between HGSOC primary and metastatic tumors have also been described [3, 4] . One study demonstrated that stable and/or regressing tumors lacked common neoepitopes and mutations compared to progressing tumors in the same patient [3] , implicating non-somatic factors within the TME as critical determinants of immune response and overall tumor fate. Multiregion sampling has revealed extensive variation between subpopulations of cells within a single tumor [5] [6] [7] , allowing individual tumor samples to have multiple subtype signatures present with differing levels of activation [8] . Single-cell RNA-Seq of HGSOC samples has revealed grade-specific and cell type-specific transcriptional profiles present within individual tumor specimens [5] . The presence of subclonal cell populations within primary and/or metastatic tumors has been demonstrated to influence the state of immune infiltration and activation [6] .
In this study, we investigated proteomic and transcriptomic heterogeneity in the TME from a single representative HGSOC patient tumor using laser microdissection of spatially separated tumor "core" regions throughout the depth of the tumor specimen, enriched tumor epithelium and stromal cell populations, as well as whole tumor harvests at ~200 µm intervals. These results reveal stark molecular heterogeneity in the HGSOC tumor microenvironment and underscore the need to account for compartmental heterogeneity in the TME in molecular profiling analyses.
Results

Proteogenomic analyses of discrete cellular populations within a single HGSOC tumor using locoregional multi-sampling
Consecutive thin sections (~200) were generated from a single snap frozen primary HGSOC tumor to support multi-region sampling by LMD followed by integrated quantitative proteomics and transcriptomics ( Figure 1A) . Tumor "cores" represent defined sub-populations of tumor epithelium that were collected as technical replicate areas from alternating tissue sections spanning the entirety of the patient tumor and combined into four independent replicate sample sets to support proteome and transcriptome analyses. Enriched tumor epithelium, stromal cells, as well as whole tumor collections representing all material on a single tissue section, were collected at ~200 µm intervals from alternating sections at nine different points throughout the tumor block (Figure 1 B) . Representative post-LMD collections were imaged along with adjacent hematoxylin and eosin (H&E) stained tissue sections to enable co-registration and automated quantification of tumor and stroma cell populations collected (Supplemental Table 1 ) for comparison with manual assessment by a board-certified pathologist (UNMR, Supplemental Table 2 ). Multiregion protein samples were analyzed by quantitative proteomics using a multiplexed, isobaric tagging methodology (tandem mass tags (TMT)-10) and RNA samples by targeted RNA-Seq analyses.
These studies quantified a total of 6,053 proteins (Supplemental Table 3 ) ( Supplemental Table 4) and 20,784 transcripts (Supplemental Tables 5 and 6 ) across all samples.
Tumor and stromal cell populations exhibit diverse proteogenomic profiles
Unsupervised hierarchical cluster analysis of protein (Supplemental Table 7 ) or transcript (Supplemental Table 8 ) abundance revealed distinct sub-clustering of tumor cores, enriched tumor epithelium and stroma, as well as whole tumor collections ( Figures 2A and B ). Two predominant clusters stratifying tumor cores and tumor epithelium from stroma and whole tumor collections are apparent. Notably, the cryopulverized tissue proteome exhibited an intermediate cluster between these two sample groups (Figure 2A ), suggesting this sample type represents a mixture of these cellular populations.
Distribution of individual epithelial markers, i.e. CA-125 (MUC16), KRT19 and CDH1, and stromal markers, i.e. VCAN, and FAP in HGSOC are highlighted for ( Figure 2C ). As expected, CA-125 and CDH1 are most abundant in the tumor cores and LMD enriched tumor epithelium collections and were least abundant in LMD enriched stroma and whole slide harvests.
VCAN and FAP expression, in contrast, were highest in LMD enriched stroma and whole slide harvests, consistent with these proteins being strong markers of stroma [9, 10] . Cell type enrichment scores using the transcript expression data was performed using xCell (Supplemental Table 9 ) [11] . Except for Cores 4A/B, all of the LMD tumor cores and LMD enriched tumor epithelium collections correlated most strongly with epithelial cell markers, while the LMD enriched stroma and whole slide harvests had the highest correlation with fibroblast markers, stroma and microenvironment scores ( Figure 2C ).
A Spearman rank correlation matrix between 5,742 proteins co-quantified proteins and transcripts revealed concordant results for corresponding samples (Figure 3 ). Proteins and corresponding transcripts for a given sample largely clustered with other harvests from the same LMD collection type (e.g. Core 1A protein clustered most to its corresponding transcript, while next nearest to other core collections). Unexpectedly, stromal transcripts clustered most strongly with the proteomes from the whole slide harvests. Within the core samples, the strongest correlations, apart from intra-core comparisons, were between the "A" and "B" replicates for each core. The A and B replicates for each core at the proteome-only and transcriptome-only levels had Supervised analyses of the proteomic and transcriptomic data revealed common canonical pathways, defined by Ingenuity Pathway Analysis (IPA), that were consistently elevated-or decreased within LMD collection types (Table 1A) . Aryl hydrocarbon receptor signaling, and the endocannabinoid cancer inhibition pathway were among the top 5 pathways most activated in LMD enriched tumor epithelium relative to stroma in both the proteomic and transcriptomic datasets. Conversely, IL-8 signaling and GP6 signaling were among the most highly downregulated pathways (least activated in enriched tumor epithelium relative to stroma) according to our proteomic and transcriptomic data. Diseases and biofunctions enriched included activation of organismal death, morbidity and mortality, and bleeding in LMD enriched tumor epithelium relative to stroma in both proteome and transcriptome data (Table 1B) . Organization of the cytoplasm and cytoskeleton, as well as cell movement and migration were among the biofunctions predicted to be inhibited in tumor relative to stroma. Genes encoding known drug targets which were differentially expressed (LIMMA adjusted p-value <0.01) between the LMD enriched tumor and LMD enriched stroma were identified in the proteomic and transcriptomic data with Log2 fold-changes > ±1 are listed in Supplemental Table 10 . Similar results were not seen using the proteomic data.
Intratumor Proteogenomic Heterogeneity Impacts Prognostic Molecular Signatures
Correlating with Altered Disease Outcome in HGSOC
Several large-scale studies have aimed to categorize HGSOC patients into subtypes having distinct molecular signatures correlated with unique prognostic outcomes, primarily using genomic and/or transcriptomic data from whole tumor specimens qualified above a set tumor cellularity/purity threshold [8, [12] [13] [14] [15] [16] [17] . Konecny et al applied transcriptional profiling to HGSOC data to determine gene expression signatures and classified the 174 cases into 4 transcriptional subtypes with unique prognostic significance [13] . Per their categorization of tumors into immunoreactive, differentiated, proliferative, and mesenchymal subtypes, patients whose tumors were characterized by mesenchymal signatures had the worst prognosis. We compared the abundance of 401 transcripts matching 635 subtype signature genes (Supplemental Table 4 , [13] ), ( Figure 4 , Supplemental Table 11 ) revealing that transcripts from LMD enriched tumor cores and tumor epithelium were strongly correlated with the differentiated subtype and inversely correlated with the prognostically-poor mesenchymal subtype. Contrary to this, the transcript profile from LMD enriched stroma were strongly correlated to the prognostically-poor mesenchymal subtype.
These results were largely recapitulated at the proteomic level from which we co-quantified 123 gene products from the Konecny et al. transcript prognostic signature set ( Figure 4 ). Our proteinlevel data showed an equivalently negative correlation between the mesenchymal subtype and LMD enriched tumor cores and epithelium, yet a strong correlation between this molecular subtype and the proteomes from the LMD enriched stroma and whole tissue harvests.
We further framed our transcriptomic data against the Liu et al signature genes associated with tumor invasiveness thought to influence success of complete surgical debulking [15] .
Comparing the 11 transcripts of the Liu et al dataset revealed that gene expression was positively correlated with our LMD enriched stroma and whole tissue collections ( Figure 4 ).
Discussion
Ovarian cancers are typically diagnosed at an advanced stage after the accumulation of numerous molecular alterations [18] . In this study, we have demonstrated that LMD enrichment reveals extensive intratumoral proteogenomic heterogeneity, which has critical implications for clinical diagnosis and implementation of appropriate therapeutic interventions, similar to what has recently been described in hepatocellular carcinoma [19] .
In an unsupervised hierarchical cluster analysis of proteins ( Figure 2A ) and transcripts ( Figure 2B ), all samples of the same LMD collection type clustered together. We found that many transcripts and/or their associated proteins were negatively correlated with the abundance trends of established diagnostic and prognostic signatures within discrete cell populations, as recently described by Zhang et al [20] . The clinical relevance of this finding is born out in correlations at the transcript and protein level for each LMD enriched collection with four HGSOC prognostic molecular subtypes described by Konecny et al [13] (Figure 4 ). Furthermore, we observe profoundly unique transitioning of molecular subtype assignment based on sampling of the tumor microenvironment at the level of the proteome versus the transcriptome. We further note the correlation of protein and transcript abundance is higher in tumor epithelium versus stroma collections and is likely attributed to the secretory nature of stroma cells [21] . This is supported by the higher correlation of transcript abundance in stroma with protein abundance in whole tumor collections where we also collect extracellular matrix. The predictive value for estimating patient outcome through molecular subtype assignment (using the molecular prognostic signatures identified by Konecny et al. [13] ) showed a median survival difference of two years depending on whether the tumor epithelium or stroma and/or mixed tissue is sampled; notably the contribution of the stromal microenvironment to the mesenchymal signature has been recently described [20, 22] . Taken together, these observations provide evidence for the existence of a pathological ovarian stroma and the proposed role of cancer-associated fibroblasts contributing to disease development and/or progression [23] [24] [25] [26] . Assignment of the cryopulverized tissue in our study to a particular subtype was less clear due to profound signal averaging of the proteome (Figure 4 ).
Our results suggest that molecular signatures developed to date have reflected variations in tumor purity that differentially impact outcome; specifically, lower tumor purity contributes to the assignment of tumors to poorer prognostic outcome. Tumors with more interceding stroma have lower resectability that decreases the likelihood of achieving compete resection (R0) during surgical debulking, leading to worse outcome [27, 28] . TCGA and other large-scale tumor characterization efforts to date have applied pre-determined tumor purity cutoff levels to include predominantly high purity tumors in their studies. As a result, molecular drivers of disease progression specific to prognostically poor/low purity tumors are frequently missed [2, 29] , as recently realized for colon cancer [30] and gliomas [31] .
We demonstrate the unexpected stromal distribution of many markers previously published as correlative with residual disease and/or suboptimal cytoreduction in ovarian cancer (Figures 2   and 4 and Supplemental Tables 3 and 6 ) [14, 15] . Among these, FABP4 and ADH1B expression were associated with significantly higher levels of residual disease [14] . Expression and shedding of AKAP12 has been recently described in isogenic cell line models of paclitaxel resistance and elevation of AKAP12 transcript also correlated with decreased survival in HGSOC patients [32] .
We observe AKAP12 transcript is elevated in stroma versus tumor epithelium (data not shown)
suggesting that elevation of AKAP12 in drug-resistant HGSOC cells may be due to chemotherapyinduced epithelial to mesenchymal transition and association with poor disease outcome may correlate with patients harboring lower-purity, likely mesenchymal-subtype tumors. COL11A1 transcripts were abundant in the stroma and some of the whole tumor collections, consistent with implications of COL11A1 overexpression by cancer-associated fibroblasts (CAFs) [24] . PTEN [33] and TP53 [34] mutations and/or loss are well-recognized alterations in HGSOC, and in some cases the presence of BRCA1/2 somatic mutations [12] may be predictive of outcome. Functional loss of BRCA1 has been correlated with dysregulation of several proteins involved in actin cytoskeletal and cell adhesion remodeling for cell migration in epithelial ovarian cancers [35] .
PTEN and BRCA1 transcripts were overall reduced in the cores and LMD enriched tumor epithelium collections, although some pure tumor epithelial fractions showed elevated levels.
Compartmentalized expression of genes encoding known anticancer drug targets [36] was found in both the LMD enriched tumor epithelium and stroma collections (Supplemental Table   10 ). VEGFA and FLT1 (also known as VEGFR1) are targets of bevacizumab, an anti-angiogenic therapy often used in treating HGSOC patients [37] . Dysregulated VEGF/VEGFR expression has been demonstrated to contribute to epithelial ovarian cancer development and/or progression through increased vascularization and improved survival of endothelial cells via anti-apoptotic signaling in the newly formed vessels [38, 39] , though bevacizumab targeting of VEGF/VEGFR has disputed levels of improvement on HGSOC patient survival [40] . In our study, VEGFA transcript expression was significantly enriched in tumor epithelium whereas transcript expression of FLT1/VEGFR1 was enriched in LMD enriched stroma. Several additional drugs often employed in the clinical management of HGSOC patients [36] target genes that we find to be significantly elevated in LMD enriched stroma relative to tumor epithelium, including imatinib, paclitaxel, gemcitabine, doxorubicin, and crizotinib.
In conclusion, we demonstrate a critical need to account for cellular subtype and regional TME proteogenomic heterogeneity in cancer molecular profiling efforts that will substantially enable in-depth characterization of spatially distributed subclonal cell populations that have underappreciated roles in driving carcinogenesis. Further work in this direction will aid clinical diagnosis, improve the efficacy of therapeutic intervention, and increase capabilities to identify druggable molecular markers of disease development and progression. 
Methods
Tissue Specimen
A surgically resected primary HGSOC specimen was obtained from a BRCA1 
Laser Microdissection
Four regionally separated areas within the tissue were discretely laser microdissected for isolation of pure tumor epithelium on a LMD7 (Leica Microsystems) from each of 100 slides for proteomics or 50 slides for transcriptomics. These four microdissected "cores" were pooled from approximately 1 mm 2 per slide for a depth spanning the entire block (1 mm x 1 mm x 2 mm). An adjacent 1 mm 2 was microdissected to serve as a replicate from each core; in total each core plus their respective adjacent replicate regions covered an approximate 2 mm x 2 mm x 2 mm area. For a set of 9 sections (200 µm apart) each for proteomics and transcriptomics, all remaining tumor epithelium (between 20-44 mm 2 /section) and stroma (44-80 mm 2 /section) were discretely collected after isolation of the 8 core regions. A second set of 9 sections was used for non-discrete whole-slide mixed tissue harvests of all remaining tissue (96-155 mm 2 /section), with the exclusion of necrosis, blood, and fat. Microdissected tissue was collected into LC-grade water (Fisher Scientific) or Buffer RLT (Qiagen) for proteomic or transcriptomic analysis, respectively.
OracleBio Image Analysis
Pre-and post-LMD images were collected using the Aperio ScanScope XT slide scanner 
Pathology Review
Reference glass H&E sections were manually reviewed by a board-certified pathologist (UNMR) for estimation of percent tumor cellularity and composition of the TME. Cellular features examined included the percent by area of necrosis, stroma, normal ovarian epithelium, lymphocytes, and polymorphonuclear leukocytes (PMN).
Peptide Preparation for TMT LC-MS/MS
LMD tissue in LC-grade water was dried, re-suspended in 100 mM triethylammonium bicarbonate (TEAB)/10% acetonitrile (ACN), and digested using SMART trypsin ( Thirty-six concentrated fractions were generated by pooling the samples in a serpentine manner.
Ten percent (volume) of each fraction was removed for LC-MS/MS.
Liquid Chromatography-Tandem Mass Spectrometry
The TMT-10 sample multiplex bRPLC fractions ( precursor selection mode was set to "Peptide" and MS1 peptide molecular ions selected for HCD were restricted to z = +2, +3 and +4. The RF lens was set to 30% and both MS1 and MS2 spectra were collected in profile mode. Dynamic exclusion (t=20s at a mass tolerance=10 ppm) was enabled to minimize redundant selection of peptide molecular ions for HCD. Normalized Log2-transformed protein-level abundance for each TMT-10 multiplex were merged and protein-level abundance for proteins not quantified in all samples, but in ≥50%, were imputed using a k-nearest neighbor (k-NN) strategy using pamr prediction analysis for microarrays R- Table 5 ). Normalized RPM-level transcript abundances were calculated relative to the average RPM abundance quantified across all samples for a given transcript followed by Log2 transformation (Supplemental Table 6 ).
Quantitative Proteomic Data Processing Pipeline for Global Proteome Analysis
Bioinformatic and Statistical Analyses
Unsupervised analyses were performed using protein and transcript alterations exhibiting 
Supplementary Discussion
Images were evaluated digitally via OracleBio's image analysis software and manually by a pathologist for tumor purity, necrosis, immune involvement overall and in the LMD collections.
There was significant discrepancy regarding estimation of tumor purity between the automated and manual evaluations. Digital analysis estimated 23-56% tumor cellularity at different depths of the block, calculated as dissection area ROI / annotated tissue area (Supplemental Table 1 ). The software estimated that the median cell number per area is approximately 7,482 cells/mm 2 . By cell type, this represents an average of 7,527 ± 172 tumor cells (n=15 protein and RNA collections) or 3,899 ± 263 stroma cells (n=6 protein and RNA collections) harvested by LMD per mm 2 of tissue area (Supplemental Table 1 ). Given the average mammalian cell is ~20 µm and the tissue was cut into 10 µm sections, this equates to 267 pg protein/cell, consistent with previous estimates [45] .
Comparatively, manual review estimated 75-95% tumor cellularity (Supplemental Table 2 ). This difference can likely be attributed to the presence of small regions of interceding stroma and other cell types in and around the tumor epithelium, which were excluded from the LMD tumor epithelium harvests.
Supplemental Table Legends
Supplemental Table 1 . LMD enriched tumor epithelium and stroma cell areas acquired by laser microdissection and automated analyses of collected regions of interest (ROI). ROI are denoted as millimeter squared (mm 2 ) areas, cell nuclei as µm 2 areas or as total cell counts derived from cellular nuclei measured in LMD enriched tumor or stroma ROIs. Table 7 . Unsupervised analysis of protein abundance (median absolute deviation > 0.5).
Supplemental
Supplemental Table 8 . Unsupervised analysis of transcript abundance (Log2 fold-change abundances with median absolute deviation > 0.5).
Supplemental Table 9 . 
